Neos Therapeutics, Inc. (NEOS)

[BioSpecialist]

Burn-rate will drop now after their Drugs completed clincal trials and are under review by FDA . Im in for the run up with first Approval expected in 2Q and another one in 4Q . Cash is enough to keep them through 3Q so there is time to push the stock much higher especially with FDA approval .The Drugs are very attractive so maybe cash coming in through Partnerdeals even Buyout is possible because Neos is dirt cheap .